HOPE Scientific studies
COVID vaccination: Efficacy, risk and safety study (COVERS)
Study: COVID vaccination: Efficacy, risk and safety study (COVERS)
Collaborating parties: Region Skåne and Lund University
Background and purpose
The COVID-19 pandemic has had a significant impact on society as a whole with enormous financial cost as well as increased morbidity and mortality. The COVID-19 vaccination makes it possible to reduce continued morbidity and mortality caused by the pandemic. Thanks to major effort, development of the vaccine has been able to proceed at record pace without compromising safety checks. At the same time, much remains unknown with regard to the effect and side effects of the different vaccines. The purpose of this study is therefore to monitor the protective effect and the short and long-term side-effects. The responsible research body for the study is Region Skåne.
A sample of people who get vaccinated are asked if they want to be involved in this study. Individuals consent to participation in the study via HOPE App. In addition to offering an automated information flow that provides step-by-step assistance to those participating in the study, the App also offers appointments. The user is notified when it is time to perform a new activity.
A blood sample will be taken (approx. 8 ml) in connection with vaccination and after 1, 6, 12 and 24 months. This is done to check the antibody response to SARS-CoV-2 and to investigate the duration of the antibody response.
HOPE Corona ensures that data is always used in accordance with statutory requirements and in a secure, responsible and considerate manner. In addition to using the HOPE App for the automated testing process, HOPE Platform is used to manage consent and for data processing.
HOPE Corona processes and shares user information in the study in a safe and secure manner with the support of the General Data Protection Regulation (GDPR).